parsaclisib
Showing 1 - 21 of 21
Follicular Lymphoma Trial in Shanghai (lenalidomide, rituximab, parsaclisib)
Not yet recruiting
- Follicular Lymphoma
- lenalidomide
- +2 more
-
Shanghai, Shanghai, ChinaRuijin hospital, school of medicine, Shanghai jiao tong universi
May 10, 2023
Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) Trial (parsaclisib, rituximab, obinutuzumab)
Withdrawn
- Follicular Lymphoma ( FL)
- Marginal Zone Lymphoma (MZL)
- parsaclisib
- +2 more
- (no location specified)
Jul 14, 2022
Mantle Cell Lymphoma Trial (parsaclisib, rituximab, bendamustine)
Withdrawn
- Mantle Cell Lymphoma
- parsaclisib
- +3 more
- (no location specified)
Apr 22, 2022
Advanced Malignancies Trial in United States (parsaclisib)
Completed
- Advanced Malignancies
- parsaclisib
-
Tustin, California
- +3 more
Aug 16, 2022
Peripheral T-Cell Lymphoma Trial in Zhengzhou (Parsaclisib, Chidamide)
Not yet recruiting
- Peripheral T-Cell Lymphoma
- Parsaclisib
- Chidamide
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Dec 26, 2021
Advanced Malignancies Trial in United States (parsaclisib)
Completed
- Advanced Malignancies
- parsaclisib
-
Rialto, California
- +4 more
Mar 28, 2022
Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous
Recruiting
- Recurrent Anaplastic Large Cell Lymphoma
- +8 more
- Parsaclisib
- Romidepsin
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Apr 6, 2022
Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma Trial in Japan (tafasitamab, lenalidomide, parsaclisib)
Recruiting
- Non Hodgkins Lymphoma
- Diffuse Large B-cell Lymphoma
- tafasitamab
- +3 more
-
Aichi, Japan
- +4 more
Jan 24, 2022
Lymphoma Trial in Japan (Parsaclisib)
Active, not recruiting
- Lymphoma
- Parsaclisib
-
Aichi, Japan
- +5 more
Jul 28, 2022
Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma Trial in Worldwide (tafasitamab, parsaclisib)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Non Hodgkin Lymphoma
- tafasitamab
- parsaclisib
-
Birmingham, Alabama
- +49 more
Sep 21, 2022
Autoimmune Hemolytic Anemia Trial in Worldwide (Parsaclisib)
Active, not recruiting
- Autoimmune Hemolytic Anemia
- Parsaclisib
-
Washington, District of Columbia
- +11 more
Aug 26, 2022
Breast Cancer, Breast Tumors, Triple Negative Breast Cancer Trial (Parsaclisib)
Withdrawn
- Breast Cancer
- +3 more
- Parsaclisib
- (no location specified)
Nov 2, 2020
Ann Arbor Stage II DLBCL, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma Trial in Scottsdale,
Recruiting
- Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
- +13 more
- Cyclophosphamide
- +6 more
-
Scottsdale, Arizona
- +2 more
Jun 1, 2022
Lymphoma Trial in Worldwide (Parsaclisib, Hexal, Gazyvaro)
Completed
- Lymphoma
- Parsaclisib
- +2 more
-
Gilbert, Arizona
- +20 more
Dec 1, 2021
Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis Trial in Worldwide (parsaclisib, ruxolitinib,
Recruiting
- Myelofibrosis
- +3 more
- parsaclisib
- +2 more
-
Anchorage, Alaska
- +172 more
Dec 1, 2022
Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis Trial in Worldwide (parsaclisib, ruxolitinib,
Recruiting
- Myelofibrosis
- +3 more
- parsaclisib
- +2 more
-
Berkeley, California
- +176 more
Dec 1, 2022
Pemphigus Vulgaris Trial (Parsaclisib)
Withdrawn
- Pemphigus Vulgaris
- Parsaclisib
- (no location specified)
Sep 11, 2019